Syneos Health Expands DCT Capabilities

Combining Awareness and Innovation

Research shows GenAI has greater potential for a more immediate impact than previous digital technologies implemented in healthcare.

Study Finds Low Representation of Disabled Participants in Cardiac Clinical Trials

Jared Baeten, Vice President, Clinical Development, HIV Franchise Head at Gilead Sciences highlights how awareness and clinical innovation have transformed research in the HIV space.

© Jakub Krechowicz - © Jakub Krechowicz - stock.adobe.com

Despite regulatory guidance, disability status is frequently unreported or overlooked in trial design.

SCOPE EUROPE 2023 Recap

October 31st 2023

Promising Trial Data Lead to FDA Fast Track Designation for Breast Cancer Combination Therapy

Insightful sound bytes from KOLs attending SCOPE EUROPE 2023.

FDA Warns of Rare But Serious Reaction to Antiseizure Medications

FDA grants to expedite review of zotatifin plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for patients with ER–positive, HER2-negative advanced or metastatic breast cancer.

Image credit: Dr_Microbe | stock.adobe.com

November 30th 2023

Will Generative AI Live Up to its High Expectations in Healthcare?

Included in the FDA warning were levetiracetam, under the brand names Keppra and Keppra XR; Elepsia XR; Spritam; and clobazam, under the brand names Onfi and Sympazan.

Related Content

December 4th 2023

Combining Awareness and Innovation

Research shows GenAI has greater potential for a more immediate impact than previous digital technologies implemented in healthcare.

Study Finds Low Representation of Disabled Participants in Cardiac Clinical Trials

Jared Baeten, Vice President, Clinical Development, HIV Franchise Head at Gilead Sciences highlights how awareness and clinical innovation have transformed research in the HIV space.

Despite regulatory guidance, disability status is frequently unreported or overlooked in trial design.

SCOPE EUROPE 2023 Recap

October 31st 2023

Promising Trial Data Lead to FDA Fast Track Designation for Breast Cancer Combination Therapy

Insightful sound bytes from KOLs attending SCOPE EUROPE 2023.

FDA Warns of Rare But Serious Reaction to Antiseizure Medications

FDA grants to expedite review of zotatifin plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for patients with ER–positive, HER2-negative advanced or metastatic breast cancer.

November 30th 2023